Analyst Price Targets — ACRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 5, 2026 10:53 am | Biren Amin | Piper Sandler | $11.00 | $4.53 | TheFly | Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler |
| May 5, 2026 8:29 am | — | Guggenheim | $12.00 | $4.53 | TheFly | Aclaris Therapeutics initiated with a Buy at Guggenheim |
| April 29, 2026 11:44 am | Martin Fan | Wedbush | $10.00 | $4.22 | TheFly | Aclaris Therapeutics price target raised to $10 from $8 at Wedbush |
| April 16, 2026 10:44 am | — | UBS | $10.00 | $3.93 | TheFly | Aclaris Therapeutics initiated with an Outperform at Oppenheimer |
| January 30, 2026 12:09 pm | Adam Vogel | Craig-Hallum | $10.00 | $3.43 | TheFly | Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy |
| November 19, 2024 7:35 am | Julian Harrison | BTIG | $8.00 | $3.14 | StreetInsider | BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 19, 2024 7:34 am | Roger Song | Jefferies | $7.00 | $3.14 | StreetInsider | Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 6, 2024 5:46 pm | Alex Thompson | Stifel Nicolaus | $3.00 | $2.28 | StreetInsider | Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel |
| December 1, 2022 5:35 am | — | Goldman Sachs | $25.00 | $15.22 | Benzinga | Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25 |
Latest News for ACRS
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
Aclaris Therapeutics NASDAQ: ACRS executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispecific antibody.
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACRS.
U.S. House Trading
No House trades found for ACRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.